The following active-site kinase inhibitors were dissolved in DMSO and used for in vivo kinase inhibition and in vitro phosphorylation experiments: mTOR kinase inhibitor PP242 (Selleckchem), CDK1 kinase inhibitor RO-3306 (Calbiochem), and pan Aurora kinase inhibitor VX-680 (Selleckchem).
Vx 680
Manufactured by Selleck Chemicals
Sourced in United States
VX-680 is a laboratory instrument used for the precise measurement and analysis of various substances. It is designed to provide accurate and reliable data to support scientific research and testing.
Automatically generated - may contain errors
Lab products found in correlation
Mln8237, by Selleck Chemicals (6 mentions)
Dimethyl sulfoxide (dmso), by Merck Group (6 mentions)
Nocodazole, by Merck Group (5 mentions)
Zm447439, by Bio-Techne (4 mentions)
Mg132, by Merck Group (4 mentions)
Bi2536, by Selleck Chemicals (4 mentions)
Doxycycline, by Takara Bio (3 mentions)
Fetal bovine serum (fbs), by Thermo Fisher Scientific (3 mentions)
Reversine, by Merck Group (2 mentions)
Monastrol, by Merck Group (2 mentions)
Protease inhibitors cocktail, by Merck Group (2 mentions)
Gsk923295, by Selleck Chemicals (2 mentions)
Nu9056, by Bio-Techne (2 mentions)
Roscovitine, by Merck Group (2 mentions)
Dmem medium, by Thermo Fisher Scientific (2 mentions)
Cycloheximide (chx), by Avantor (2 mentions)
Nocodazole, by Selleck Chemicals (2 mentions)
Puromycin, by Selleck Chemicals (2 mentions)
Pha 680632, by Selleck Chemicals (2 mentions)
H1299, by American Type Culture Collection (2 mentions)
31 protocols using vx 680
1
Kinase Inhibitor Dissolution Protocol
2
Mitotic Inhibitors and Modifiers Protocol
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
Nocodazole (100 ng/mL, ≥99%), monastrol (50 μM, ≥98%), MG132 (10 μM, ≥90%), OA (500 nM, ≥92%), Reversine (1 μM, ≥98%), Roscovitine (20 μM, ≥98%), NAM (5 mM, ≥99.5%), and TSA (1 μM, ≥98%) were from Sigma. MG149 (100 μM, >99%) was from Axon. NU9056 (20 μM, >98%), ZM447439 (2 μM, >99%) were from Tocris Bioscience. GSK923295 (50 nM, >99%), BI2536 (100 nM, >99%), VX-680 (500 nM, >99%) was from Selleckchem. The protease inhibitors cocktail was from Sigma.
3
Breast Cancer Samples Protein Extraction
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
All breast cancer samples were obtained from newly diagnosed patients with prior patient consent and the approval of the Institutional Clinical Ethics Review Board in the 1st Affiliated Hospital of Dalian Medical University. Samples were kept in liquid nitrogen for protein extraction.
HEK293T cell and human breast cancer cells (SKBR-3, BT-549) were cultured in DMEM medium (Invitrogen) or RMPI 1640 medium (Invitrogen) supplemented with 10% (v/v) fetal bovine serum (FBS, HyClone). The immortalized breast epithelial cell MCF-10A was cultured in DMEM/F12 medium (Invitrogen) supplemented with 5% (v/v) horse serum (HS, HyClone), 20ng/ml EGF, 100ng/ml cholera toxin, 0.01mg/ml insulin and 500ng/ml hydrocortisone. All cell lines were purchased from American Type Culture Collection (ATCC) and incubated at 37°C in humidified 5% CO2 incubator.
Reagents used were purchased as followed: VX680 (Selleck Chemicals, 639089-54-6), 3-Methyladenine (3-MA, Sigma, M9281), rapamycin (Sigma, 37094), SB216763 (Sigma, S3442), z-VAD-FMK (Beyotime, C1202), lithium chloride (LiCl, Sangon Biotech, LDB0307), doxorubicin (KeyGEN BioTECH, KGA8182). Nutrient deprivation was performed using Hank's balanced salt solution (HBSS, HyClone). To avoid any supplementary stress, HBSS was preheated at 37°C before added into cells.
HEK293T cell and human breast cancer cells (SKBR-3, BT-549) were cultured in DMEM medium (Invitrogen) or RMPI 1640 medium (Invitrogen) supplemented with 10% (v/v) fetal bovine serum (FBS, HyClone). The immortalized breast epithelial cell MCF-10A was cultured in DMEM/F12 medium (Invitrogen) supplemented with 5% (v/v) horse serum (HS, HyClone), 20ng/ml EGF, 100ng/ml cholera toxin, 0.01mg/ml insulin and 500ng/ml hydrocortisone. All cell lines were purchased from American Type Culture Collection (ATCC) and incubated at 37°C in humidified 5% CO2 incubator.
Reagents used were purchased as followed: VX680 (Selleck Chemicals, 639089-54-6), 3-Methyladenine (3-MA, Sigma, M9281), rapamycin (Sigma, 37094), SB216763 (Sigma, S3442), z-VAD-FMK (Beyotime, C1202), lithium chloride (LiCl, Sangon Biotech, LDB0307), doxorubicin (KeyGEN BioTECH, KGA8182). Nutrient deprivation was performed using Hank's balanced salt solution (HBSS, HyClone). To avoid any supplementary stress, HBSS was preheated at 37°C before added into cells.
4
Synergistic Anticancer Drug Combination Screening
5
Apoptosis Induction by Kinase Inhibitors
6
Proliferation and Inhibition Assay for NPCs
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
For cell proliferation estimation, EdU was pulsed in cells for 24–72 h before fixation, and stained according to the manufacturer's instructions (Click‐iT EdU assay kit, Life Technologies). For inhibitor experiments, wherever necessary, NPCs were treated with the Cdk1 inhibitor, olomoucine (Sigma‐Aldrich; 25 μM), or VX680 (Selleckchem; 0.5 μM) for 4 days, fixed, and analyzed by microscopy.
For RNAi treatments, NPCs were electroporated using the Neon Transfection System with 100 nmol of siRNA targeting human NDE1 and OFD1 mRNA. NDE1: siGENOME Human NDE1 (54,820) siRNA‐SMARTpool (M‐020625‐00‐0005) OFD1: siGENOME Human OFD1 (8481) siRNA‐SMARTpool (M‐009300‐02‐0005). Negative controls were performed with non‐targeting siRNA (scrambled; 100 nmol, AllStars Negative control siRNA; Qiagen). Electroporation using 100 nmol siRNA was repeated on day 3. siRNA‐treated NPCs were fixed on day 7 for further analysis.
For RNAi treatments, NPCs were electroporated using the Neon Transfection System with 100 nmol of siRNA targeting human NDE1 and OFD1 mRNA. NDE1: siGENOME Human NDE1 (54,820) siRNA‐SMARTpool (M‐020625‐00‐0005) OFD1: siGENOME Human OFD1 (8481) siRNA‐SMARTpool (M‐009300‐02‐0005). Negative controls were performed with non‐targeting siRNA (scrambled; 100 nmol, AllStars Negative control siRNA; Qiagen). Electroporation using 100 nmol siRNA was repeated on day 3. siRNA‐treated NPCs were fixed on day 7 for further analysis.
7
Culturing and Treating Cell Lines
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
Gastric cell lines AGS and BGC823 were cultured in RPMI 1640 (Gibco, Carlsbad, CA, USA) HEK293T and mouse embryonic fibroblast (MEF) were cultured in Dulbecco's modified eagle medium (DMEM) (Gibco). Cell culture media were supplemented with 10% heat-inactivated fetal bovine serum (Gibco), 100 U/ml ampicillin and 100 μg/ml streptomycin (Gibco). Treatments with doxorubicin (Sigma-Aldrich, St Louis, MO, USA), doxycycline (Clonetech, Shiga, Japan), VX-680 (Selleck Chemicals, Kava Technology), cycloheximide (Amresco, Solon, OH, USA) and MG132 (Sigma-Aldrich) were carried out as indicated. Cells were transfected using lipofectamine 2000 transfection reagent (Invitrogen, Carlsbad, CA, USA). For details, see Supplementary Materials and Methods .
8
Radiotherapy and VX680 Inhibit GBM Growth
9
AURKA and BET Bromodomain Inhibitors in MDA-MB-231 Cells
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
AURKA inhibitors VX‐680 and MLN8237 and bromodomain and extra‐terminal (BET) bromodomain inhibitor JQ1 were obtained from Selleck Chemicals (Houston, TX, USA) and dissolved in dimethyl sulfoxide (DMSO). MDA‐MB‐231 cells were treated with 0.1, 0.2, and 0.4 μmol/L VX‐680 and 0.1, 0.2, 0.4, and 0.8 μmol/L MLN8237 for 24 h. MDA‐MB‐231 cells with NLS‐AURKA were treated with 1 and 5 μmol/L JQ1 for 48 h for Western blotting detection. Antibodies against AURKA and phospho‐AURKA (T288) were purchased from Sigma‐Aldrich (St. Louis, MO, USA). Glyceraldehyde 3‐phosphate dehydrogenase (GAPDH), goat anti‐mouse IgG‐horse radish peroxidase (HRP), and goat anti‐rabbit IgG‐HRP were obtained from Cell Signaling (Danvers, MA, USA). c‐Myc was purchased from Santa Cruz Biotechnology (Dallas, TX, USA). PD‐L1 was obtained from Abcam (Cambridge, MA, USA). TruStain FcX™ anti‐mouse CD16/32, PerCP anti‐mouse CD45, FITC anti‐mouse CD3, PE anti‐mouse CD4, APC anti‐mouse CD8a, and PE anti‐mouse CD69 used in flow cytometric analysis were purchased from Biolegend (San Diego, CA, USA). PE anti‐human PD‐L1 and its isotype control PE anti‐human IgGk1 were obtained from BD Pharmingen (San Diego, CA, USA).
10
Stable Cell Lines Expressing Cep68 Constructs
About PubCompare
Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.
We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.
However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.
Ready to get started?
Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required
Revolutionizing how scientists
search and build protocols!